Traws Pharma's Tivoxavir Marboxil demonstrates encouraging results as a single-dose treatment for H5N1 avian influenza, marking a potential breakthrough.
Traws Pharma's ratutrelvir demonstrates potential as a once-daily monotherapy for COVID-19, eliminating the need for ritonavir and reducing clinical rebound risk.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.